Biopharma Daily Stock Updates - 03/22/21

$XBI $147.12 +1%

Covid Updates

$MRNA +1% New supply agreement with Philippines for 7M doses of covid-19 vaccine. source


$RDHL +2% Compassionate use exemption used for several patients in Switzerland of opaganib for covid-19. source


$AZN +4% ph 3 data from study of AZD1222 in preventing covid-19. source


Pipeline Updates

$CHMA +13% New ph 3 data of MYCAPSSA in acromegaly. source


$SBBP -6% detailed Ph 3 results from RECORLEV for Cushing's syndrome presented at ENDO 2021. source


$RYTM -1% New ph 2 data of setmelanotide for HET obesity presented at ENDO 2021. source


$ETNB +7% Additional analysis of ph 1b/2a NASH study presented at ENDO 2021. source


$KURA +5% Ph 2 Tipifarnib data published in Journal of Clinical Oncology. source


$PTGX +6% Plans to initiate global registrational ph 3 of rusfertide for polycythemia vera. source


$AKRO +5% 16-wk data from cohort c in ph 2a study of efruxifermin for NASH. source


$CTIC +3% Ph 1 results of pacritinib for prevention of acute graft-versus-host disease (GVHD). source


$AGLE +9% Exclusive license agreement for pegzilarginase for ARG1-D in EU and middle east. AGLE receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the mid-twenties. source


$SESN -1% IND approval for Viniceum in China. source


$BCRX -11% Ph 1 data presented for BC9930 in PNH, pivotal trials planned for H2 2021. source


$RAPT +1% Completes enrollment in ph 1b trial of RPY193 in atopic dermatitis. source


$ODT -80% Discontinuing development of tesetaxel after feedback from FDA re: data package. source


$RCKT +1% Updated ph 1 data from RP-L301 for pyruvate kinase deficiency. source


$AVEO -1% Commercial launch of Fotivda in US. source


$ZEAL +15% FDA approval of Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. source


$PCRX +2% FDA approval of Exparel sNDA for pediatric patients. source


Financial Updates

$GLPG -1% Exercises subscription right program for new share issuance. Source


$AVEO -7% Offering. source


XOMA +3% Approval of stock dividend. source

0 comments